Sixth Street Partners’s TherapeuticsMD TXMD Stock Holding History

Sixth Street Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-124,659	Closed	-$467K	–	18
2023 Q1	$467K	Buy	+124,659	New	+$598K	0.05%	13

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Sixth Street Partners's TXMD Position: Q2 2023 in Review

Sixth Street Partners sold out of TherapeuticsMD (TXMD) in Q2 2023, closing a stake of 124,659 shares — an estimated $467K sold.

Sixth Street Partners first reported a position in TXMD in Q1 2023 and held it in 1 quarter. The position peaked at $467K in Q1 2023. 42 funds tracked by Wall St. Rank hold TXMD as of Q2 2023.

Sixth Street Partners reported no remaining TherapeuticsMD position as of Q2 2023 after selling out during the quarter.
Sixth Street Partners sold 124,659 TherapeuticsMD shares in Q2 2023, an estimated $467K.
Sixth Street Partners first reported a position in TherapeuticsMD in Q1 2023 and held it in 1 quarter.
Sixth Street Partners's TherapeuticsMD position peaked at $467K in Q1 2023.
42 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2023.

Based on Sixth Street Partners's 13F filing for Q2 2023, filed 11 Aug 2023.